Crowdonomics
All companies
KINEON logo

KINEON

Operating

Kineon, Inc.

Healthcare · Biotech · Atlanta, GA · Founded 2021

Biotech company dedicated to changing the way we approach chronic pain through light therapy products

Post-money valuation
$20.5M
As of Nov 2023 · from Kineon Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$459,677
Across 1 round since 2023
Latest share price
$1.00
Kineon Common Stock 1 offering price

Financials

FY2021–FY2025 · from SEC filings · hover any figure for its source
$0
−$198K
2021
$1K
$22
2022
$2.9M
−$107K
2023
$10.3M
−$1.9M
2024
$6.8M
−$506K
2025
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
FY2023
FY2024
FY2025
Income statement
Revenue
$0
$1,329
$2,887,269
$10,281,759
$6,785,478
Cost of goods sold
$0
$360
$549,768
$1,912,383
$1,279,184
Gross margin
73%
81%
81%
81%
Net income
-$197,792
$22
-$107,280
-$1,856,509
-$506,469
Taxes paid
$0
$0
$0
$0
$0
Balance sheet
Cash
$147,789
$66
$414,651
$488,585
$591,785
Accounts receivable
$0
$33
$0
$0
$48,547
Total assets
$157,078
$324
$905,089
$1,399,895
$1,153,932
Short-term debt
$345,915
$87
$12,360
$2,930,050
$3,090,556
Long-term debt
$0
$0
$105,595
$0
$0
Total liabilities
$345,915
$87
$117,955
$2,930,050
$3,090,556
Other
Headcount
17
17
17
17

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$20.5M
post-money
Kineon Common Stock 1

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Kineon Common Stock 1ClosedReg CF · Common Equity · via StartEngine
Raised $459.7K / $1.2MInvestors 274Post-money $20.5M

Team

3 people
Forrest SmithFounder
Chief Executive Officer, Co-Founder, Board Member

Forrest studied Chinese from the age of 14 and was fascinated with the culture from a very young age. Forrest is fluent in Chinese and has 18 years of experience in successful startup building and executive management in Asia. In 2000, Forrest started his first venture in China, a fabric sourcing company that was acquired in 2002. Over his next ten years in China, Forrest founded and managed multiple ventures from startup to acquisition, including Source Pro Asia (a small sourcing company, August Vale (tannery, leather furniture company acquired by Wilway Holdings), and most recently Illumitron (LED lighting and controls, company acquired by Cooper Lighting). Aside from his founder position in multiple companies, Forrest has held several positions, from Director of Asian Operations for a Fortune 500 company to Director of Business Development. His education includes International Baccalaureate with a focus on Chinese, Nanjing University/Johns Hopkins Center, and Georgia Tech.

Thomas SandersonFounder
Chief Operating Officer, Co-Founder, Board Member

Tom Sanderson is the COO of Kineon. An entrepreneur at heart, driven by a passion for human health and well-being, Tom has worked in international startups for more than 16 years. Born in Bahrain and raised in the North of England. Over 10 years as co-founder of a successful Film Production Studio based out of South East China - providing film services for leading global brands such as Huawei, Sennheiser, Audi, John Lewis... He firmly believes that incorporating mindfulness, health and well-being into your professional and personal life is the key to success.

Edward Sanderson
Chief Financial Officer, Board Member

Fellow of the Institute of Chartered Management Accountants. Ed has worked in the UK, Europe and the Middle East providing Board level Financial support over many years.

Names and titles as disclosed on StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 3 of 3 annual reports (FY2023–FY2025)

274 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-ARApr 17, 20260001987012-26-000002
    EDGAR
  • Form C-ARApr 14, 20250001665160-25-000656
    EDGAR
  • Form C-ARApr 19, 20240001665160-24-000401
    EDGAR
  • Form C-UDec 1, 20230001665160-23-001965
    EDGAR
  • Form C/AOct 16, 20230001665160-23-001853
    EDGAR
  • Form CAug 8, 20230001665160-23-001617
    EDGAR
Source: ManualCIK 0001987012DEShare price $1.00

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.